FDA clears Zephyr’s latest update to MATRx plus
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to medical device company Zephyr Sleep Technologies’ latest update to MATRx plus. The clearance eliminates the requirement for a nasal cannula during a sleep theranostic test and makes setting up the take-home Treatment Planning test simpler. Patients now only need a single fingertip pulse oximetry probe for the test. All existing MATRx plus users who are Connected Program subscribers

